Insulet’s Q1 Revenue Rises 33.9% to $761.7M, Price Target Cut to $216
PODD•Raymond James cut Insulet’s price target by 18% to $216 from $263, implying a 42.6% upside. In Q1 2026, Insulet posted 33.9% revenue growth to $761.7M and 39.7% adjusted EPS growth to $1.42, and raised its 2026 revenue forecast to 21–23% growth with over 25% EPS expansion.
1. Analyst Lowers Price Target
An analyst lowered Insulet’s price target by 18% to $216 from $263, implying roughly 42.6% upside and signaling market caution despite robust fundamentals.
2. Q1 Financial Performance
Insulet reported Q1 2026 revenue of $761.7 million, up 33.9% year-on-year, and adjusted EPS of $1.42, a 39.7% increase, both figures surpassing consensus forecasts.
3. Raised 2026 Outlook and Growth Drivers
Management increased its 2026 revenue growth forecast to 21–23% and expects adjusted EPS growth above 25%, driven by accelerating adoption of the Omnipod 5 system and international expansion.
